Racial Disparities in Liver Diseases
肝脏疾病的种族差异
基本信息
- 批准号:7126844
- 负责人:
- 金额:$ 18.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-30 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:antiviral agentsclinical trial phase IIIcombination therapydrug resistancehealth disparityhepatitis Chepatitis C virushepatocellular carcinomahuman datahuman therapy evaluationhuman tissueimmunopharmacologyimmunotherapyinterferonsliver disorderliver disorder chemotherapyliver pharmacologymentoring /mentormicroorganism disease chemotherapypatient oriented researchpharmacogeneticsracial /ethnic differencevirus characteristic
项目摘要
DESCRIPTION (provided by applicant):
The applicant's long-term career objective is to decrease racial disparities in liver diseases in the United States by conducting well-designed patient-oriented research and by increasing the number of highly trained research scientists engaged in patient-oriented research in digestive diseases. Chronic hepatitis C virus (HCV) infection is the most common etiology for liver cirrhosis and a major cause for primary hepatocellular carcinoma (HCC) in the US. Several well-designed population studies have found a greater HCV prevalence and both a higher HCC incidence and mortality from primary hepatocellular carcinoma in Black Americans compared to White Americans. Ironically, Blacks have a much lower rate of HCV clearance during peginterferon plus ribavirin treatment. A better understanding of the causes for health disparities based on race is a necessary to develop comprehensive strategies to improve the health of racial minorities as well as the general US populace. Dr. Howell is an established investigator with an excellent track in patient-oriented research on racial disparities. His immediate career objectives are: 1) to develop a new patient-oriented research studies investigating the basis for racial disparities in liver disease; 2) to provide high-quality mentorship for the increasing numbers of trainees interested in patient-oriented liver research at the University of Maryland, including Gastrointestinal and Infectious Diseases research training grants; and 3) to strengthen his background for future patient-oriented research projects and mentoring by completing didactic coursework in clinical investigation. The Midcareer Investigator Award in Patient-Oriented Research (K24) award will enhance the applicant's career development and future success in patient-oriented research by allowing him to decrease his patient care, teaching, and institutional service obligations and to spend more time pursuing these important goals and objectives.
描述(由申请人提供):
申请者的长期职业目标是通过进行精心设计的以患者为导向的研究和增加训练有素的研究科学家从事以患者为导向的消化系统疾病研究,减少美国肝病的种族差异。慢性丙型肝炎病毒感染是最常见的肝硬变病因,也是美国原发性肝细胞癌的主要原因。几项精心设计的人群研究发现,与白人相比,美国黑人的丙型肝炎流行率更高,肝癌发病率和原发性肝细胞癌死亡率都更高。具有讽刺意味的是,在聚乙二醇干扰素和利巴韦林联合治疗期间,黑人的丙型肝炎病毒清除率要低得多。更好地了解基于种族的健康差距的原因对于制定全面的战略以改善少数族裔和普通美国民众的健康是必要的。豪厄尔博士是一位知名的研究员,在以患者为导向的种族差异研究方面有着出色的表现。他目前的职业目标是:1)开发一个新的以患者为导向的研究项目,调查肝病种族差异的基础;2)为马里兰大学越来越多对以患者为导向的肝脏研究感兴趣的学员提供高质量的指导,包括胃肠道和传染病研究培训补助金;以及3)通过完成临床研究的教学课程,加强他对未来以患者为导向的研究项目和指导的背景。以患者为中心的研究的职业中期研究员奖(K24)将通过允许申请人减少患者护理、教学和机构服务的义务,并将更多的时间用于追求这些重要的目标和目标,来促进申请人在以患者为中心的研究中的职业发展和未来的成功。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES D HOWELL其他文献
CHARLES D HOWELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES D HOWELL', 18)}}的其他基金
RIBAVIRIN PHARMACOKINETICS, RACE AND OUTCOME OF HEPATITIS C TREATMENT
利巴韦林丙型肝炎治疗的药代动力学、种族和结果
- 批准号:
7951172 - 财政年份:2009
- 资助金额:
$ 18.31万 - 项目类别:
Ribavirin Pharmacokinetics, Race and HCV Treatment
利巴韦林药代动力学、种族和 HCV 治疗
- 批准号:
7242435 - 财政年份:2007
- 资助金额:
$ 18.31万 - 项目类别:
Ribavirin Pharmacokinetics, Race and HCV Treatment
利巴韦林药代动力学、种族和 HCV 治疗
- 批准号:
7440199 - 财政年份:2007
- 资助金额:
$ 18.31万 - 项目类别:
STUDY OF VIRAL RESISTANCE TO ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C (VIRAHEP)
慢性丙型肝炎 (VIRAHEP) 病毒抗病毒治疗的研究
- 批准号:
7376926 - 财政年份:2006
- 资助金额:
$ 18.31万 - 项目类别:
Viral Resistance to Antiviral Therapy for Hepatitis C
丙型肝炎抗病毒治疗的病毒耐药性
- 批准号:
6981318 - 财政年份:2004
- 资助金额:
$ 18.31万 - 项目类别:
相似海外基金
CLINICAL TRIAL: PHASE III, ICA-17043 WITH OR WITHOUT HYDROXYUREA IN SICKLE CELL
临床试验:III 期,ICA-17043 在镰状细胞中含或不含羟基脲
- 批准号:
7716822 - 财政年份:2008
- 资助金额:
$ 18.31万 - 项目类别:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
- 批准号:
7950848 - 财政年份:2008
- 资助金额:
$ 18.31万 - 项目类别:
CLINICAL TRIAL: PHASE III - MULTIPLE COURSES OF AZTREONAM LYSINATE FOR INHALATIO
临床试验:第三阶段 - 氨曲南赖氨酸吸入的多个疗程
- 批准号:
7716865 - 财政年份:2008
- 资助金额:
$ 18.31万 - 项目类别:
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/
临床试验:皮下重组 IL-2 在患者中的 III 期研究
- 批准号:
7717012 - 财政年份:2007
- 资助金额:
$ 18.31万 - 项目类别:














{{item.name}}会员




